Adaptive, Johnson & Johnson Innovation Announce Agreement
Complete the form below to unlock access to ALL audio articles.
Adaptive Biotechnologies has announced a biomarker discovery agreement facilitated by the Johnson & Johnson Innovation Center in California.
Under the agreement, Adaptive will use its patented immune profiling assay, immunoSEQ™, to enable an in-depth characterization of the immune response to diseases being studied and select immunology and oncology drugs being developed by Janssen Research & Development, LLC (Janssen).
The exploration of immune response may identify patient populations more likely to respond to targeted therapies based on their immune status.
“We are delighted to work so closely with Janssen to further elucidate the role that immune profiling can play in scientific research and drug development,” said Chad Robins, CEO and Founder of Adaptive Biotechnologies. “Adaptive’s corporate focus is to further understand the immune response in patients living with diseases like cancer and autoimmune disorders.”
Adaptive’s CEO Robins will be sharing this corporate focus on immune profiling to improve patient care during the upcoming JP Morgan Healthcare conference in San Francisco on January 15, 2014.
Details on Adaptive’s full suite of research and diagnostic immunosequencing assays, as well as other key partnerships, will be presented.